Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye

Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye

The combination of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is recommended as a salvage therapy for treatment-experienced chronic hepatitis C (CHC) patients. However, it is used in our country for treatment-naïve and treatment-experienced patients. This study aims to present real-world data...

Full description

Saved in:
Bibliographic Details
Main Authors: Umut Devrim Binay, Faruk Karakeçili, Bilgehan Aygen, Ayşin Kılınç Toker, İlhami Çelik, Neşe Demirtürk, Tuğçe Şimşek Bozok, Leyla Dursun, Fethiye Akgül, Güle Çınar, Özgür Günal, Ali Asan, Eyüp Arslan, Fatma Yılmaz Karadağ, Orçun Barkay, İrem Akdemir, Funda Şimşek, Emine Türkoğlu Yılmaz, Zeynep Ravza Eğilmez, Süda Tekin, The Viral Hepatitis Study Group of the Turkish Society of Clinical Microbiology and Infectious Diseases (KLİMİK)
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Viruses
Subjects:
sofosbuvir/velpatasvir/voxilaprevir
hepatitis C treatment
real-world data
Online Access:https://www.mdpi.com/1999-4915/17/7/931
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items